Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001125 · ClinicalTrials.gov registry record · Phase 1

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

A Phase 1 study of HIV Infections and Chickenpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
20
Study locations

NCT00001125 is a Phase 1 study of HIV Infections and Chickenpox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001125, a Phase 1 study of HIV Infections and Chickenpox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to see if the varicella-zoster virus (VZV) vaccine will be safe and if it can help prevent shingles in HIV-infected children who have already had chickenpox. VZV is the virus that causes chickenpox. If this virus is reactivated in the body, it can also cause shingles. Shingles is common in children with HIV who have had chickenpox, although it is usually not life-threatening. The VZV vaccine used in this study may be able to prevent HIV-positive children who have had chickenpox from developing shingles.

Interventions

  • BIOLOGICAL Varicella Virus Vaccine (Live)

Study Locations (20)

New York

  • Nyu Ny Nichd Crs - New York
  • Cornell Univ., Div. of Ped. Infectious Diseases & Immunology - New York
  • Columbia IMPAACT CRS - New York
  • Harlem Hosp. Ctr. NY NICHD CRS - New York
  • Strong Memorial Hospital Rochester NY NICHD CRS - Rochester
  • SUNY Upstate Med. Univ., Dept. of Peds. - Syracuse

California

  • Long Beach Memorial Med. Ctr., Miller Children's Hosp. - Long Beach
  • Usc La Nichd Crs - Los Angeles
  • UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS - Los Angeles
  • Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases - Torrance

Florida

  • South Florida CDTC Ft Lauderdale NICHD CRS - Fort Lauderdale
  • Univ. of Florida Jacksonville NICHD CRS - Jacksonville
  • Univ. of Miami Ped. Perinatal HIV/AIDS CRS - Miami

Massachusetts

  • HMS - Children's Hosp. Boston, Div. of Infectious Diseases - Boston
  • BMC, Div. of Ped Infectious Diseases - Boston
  • Baystate Health, Baystate Med. Ctr. - Springfield

New Jersey

  • Cooper Univ. Hosp. - Camden
  • NJ Med. School CRS - Newark

Pennsylvania

  • The Children's Hosp. of Philadelphia IMPAACT CRS - Philadelphia
  • St. Christopher's Hosp. for Children - Philadelphia

Trial Details

FieldValue
Enrollment Target 60 participants
Est. Completion 2004-03
Phase Phase 1

What the Registry Record Tells You About NCT00001125

The ClinicalTrials.gov registry entry for NCT00001125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Varicella Virus Vaccine (Live) is the first listed.

NCT00001125 reports 20 study locations spanning 6 distinct geographic areas - top geographies include New York, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00001125 about?

NCT00001125 is a clinical study titled "Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox". The purpose of this study is to see if the varicella-zoster virus (VZV) vaccine will be safe and if it can help prevent shingles in HIV-infected children who have already had chickenpox. VZV is the virus that causes chickenpox. If this virus is reactivated in the body, it can also cause shingles. S...

What is the current status of trial NCT00001125?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. Estimated completion is 2004-03.

What conditions does trial NCT00001125 study?

This clinical trial studies the following conditions: HIV Infections, Chickenpox.

What interventions are being tested in trial NCT00001125?

The interventions under investigation include: Varicella Virus Vaccine (Live) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00001125?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001125 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.